West Family Investments Inc. Boosts Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

West Family Investments Inc. raised its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 87.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,468 shares of the company’s stock after buying an additional 15,638 shares during the quarter. West Family Investments Inc.’s holdings in Takeda Pharmaceutical were worth $443,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Gold Investment Management Ltd. boosted its holdings in shares of Takeda Pharmaceutical by 2.0% in the 3rd quarter. Gold Investment Management Ltd. now owns 73,204 shares of the company’s stock worth $1,049,000 after purchasing an additional 1,428 shares in the last quarter. Smithfield Trust Co boosted its holdings in shares of Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares in the last quarter. Sage Rhino Capital LLC boosted its holdings in shares of Takeda Pharmaceutical by 14.9% in the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company’s stock worth $157,000 after purchasing an additional 1,538 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in shares of Takeda Pharmaceutical by 7.0% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock worth $362,000 after purchasing an additional 1,670 shares in the last quarter. Finally, Aaron Wealth Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock worth $331,000 after purchasing an additional 1,670 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

TAK opened at $15.00 on Friday. The stock has a 50-day moving average price of $13.55 and a 200-day moving average price of $13.91. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $47.71 billion, a P/E ratio of 37.49, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.